Imagion presents MagSense® interim study results at breast cancer meeting
Imaging agent aids in resolving nodal status MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the…
Proactiveinvestors Interviews Bob Proulx on FDA Fast Track Status for MagSense® Imaging
Proactiveinvestors interviews Bob Proulx on what FDA's designation of MagSense® imaging as a "breakthrough device" means for the company and its investors:…
HER2 Nanoparticle Safety and Specificity Data Presented at AACR 2019
Marie Zhang, PhD, Vice President of Research and Clinical Development at Imagion Biosystems, presented the poster "HER2 Functionalized Nanoparticles Are Safe…
Imagion Biosystems hits key development milestone with initiation of toxicology study
Imagion Biosystems has achieved a key milestone in its progress to first-in-human testing with the commencement of a toxicology safety study of its lead…
MagSense® Pre-Clinical Study Presented at 2018 SABCS
On Saturday, December 8, 2018, Marie Zhang, PhD presented the poster "Detection of HER2 Positive Tumor Cells Using Functionalized Iron Oxide Nanoparticles" at…
Proactiveinvestors Interviews Bob Proulx
Proactiveinvestors news media have interviewed Imagion Biosystems CEO Bob Proulx, who answers questions about the company's early cancer detection technology,…
MagSense Technology Animation
. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense®…
MagSense® Technology at ASCO 2018 Annual Meeting
The ASCO 2018 Annual Meeting abstract, "Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic…
MagSense® Pre-Clinical Safety Data from AACR 2018
Pre-clinical data on Imagion Biosystems' MagSense HER2+ cancer detection platform have shown: specific binding and detection of HER2+ tumor cells in vitro…
Late-Breaking MagSense® Safety Study Abstract Accepted for AACR 2018
Imagion Biosystems' abstract "Detection of HER2+ tumor cells using MagSense® nanoparticles: safety and sensitivity" has been accepted for the 2018 AACR meeting…